Early diagnosis of prostate cancer, AABH (Aspartyl Asparaginyl β-hydroxylase), a predictive biomarker: A serum immunoassay and personalized medicine. This is an ASCO Meeting Abstract from the 2020 ...

The NICE guideline on prostate cancer recommends that a multiparametric MRI test should be offered to people with suspected clinically localised prostate cancer. People with a significant lesion ...

The diagnostics advisory committee considered evidence on MRI fusion biopsy systems using Artemis, Biojet, BiopSee, bkFusion, Fusion Bx 2.0, FusionVu, iSR'obot Mona Lisa, KOELIS Trinity and UroNav ...

A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract ...

September is National Prostate Cancer Awareness Month, an important time to bring awareness to prostate health. The prostate gland is a male reproductive organ about the size of a ping-pong ball that ...

Microultrasonography for prostate biopsy detected clinically significant cancer at rates comparable to MRI-guided approaches. Detection rates for clinically insignificant cancers did not differ among ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

Less than 1% of patients who underwent the procedure under local analgesia and without antibiotic prophylaxis experienced post-biopsy infection, a study found. Transperineal magnetic resonance imaging ...

After a patient has undergone a prostate MRI, the images are sent to radiology to evaluate suspicious lesions. The UroNav fusion biopsy system uses this critical diagnostic information to provide ...

Compared with TRUS biopsies, MRI fusion biopsy findings are more likely to be concordant with final prostate cancer pathology at the time of radical prostatectomy, a study found. Prostate biopsies ...